Preferred Label : Hyperaldosteronism, familial, type III;
Symbol : HALD3;
CISMeF acronym : HALD3;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Fh III;
Description : This form of hyperaldosteronism is characterized by hypertension secondary to massive
adrenal mineralocorticoid production. Like patients with glucocorticoid-remediable
aldosteronism (GRA, or FH I; 103900), patients with FH III present with childhood
hypertension, elevated aldosteronism levels, and high levels of the hybrid steroids
18-oxocortisol and 18-hydroxycortisol. However, hypertension and aldosteronism in
FH III are not reversed by administration of exogenous glucocorticoids and patients
require adrenalectomy to control hypertension (Geller et al., 2008).;
Inheritance : Autosomal dominant;
Molecular basis : Caused by mutation in the member-5 subfamily-J inwardly rectifying potassium channel
gene (KCNJ5, 600734.0002);
Laboratory abnormalities : Hypercalciuria (in some patients); Hypokalemia; Paradoxical increase or no change in serum aldosterone and blood pressure after dexamethasone
administration; Decreased plasma renin activity;
Prefixed ID : #613677;
Origin ID : 613677;
UMLS CUI : C3838758;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)